Epidemiology Series Forecast Report on Essential Thrombocythemia (ET) in 9 Major Markets
Essential Thrombocythemia (ET) or Primary Thrombocythemia, is a rare, chronic myeloproliferative disorder that involves the over production of blood platelets by the bone marrow. ET is characterized by a persisting elevated platelet count >450,000/µL, with megakaryocytic hyperplasia, and patients will likely also suffer from splenomegaly and thrombotic or hemorrhagic episodes or both.
This report provides the current prevalent population for ET across 9 Major Markets (USA, France, Germany, Italy, Spain, UK, Brazil, Japan and India) split by gender and 5-year age cohort. Along with the current prevalence, the report also contains a disease overview of the risk factors, disease diagnosis and prognosis along with specific variations by geography and ethnicity.
Providing a value-added level of insight from the analysis team , several of the main symptoms and co-morbidities of ET have been quantified and presented alongside the overall prevalence figures. These sub-populations within the main disease are also included at a country level across the 10-year forecast snapshot.
Main symptoms and co-morbidities for ET include:
• Secondary myelofibrosis
• Acute myeloid leukaemia
• Anaemia
• Splenomegaly
• Hepatomegaly
• Incident thrombosis
• Deep vein thrombosis
• Pregnancy complications
This report is built using data and information sourced from the proprietary Epiomic patient segmentation database. To generate accurate patient population estimates, the Epiomic database utilises a combination of several world class sources that deliver the most up to date information from patient registries, clinical trials and epidemiology studies. All of the sources used to generate the data and analysis have been identified in the report.
Reason to buy
• Able to quantify patient populations in global ET’s market to target the development of future products, pricing strategies and launch plans.
• Gain further insight into the prevalence of the subdivided types of ET and identify patient segments with high potential.
• Delivery of more accurate information for clinical trials in study sizing and realistic patient recruitment for various countries.
• Provide a level of understanding on the impact from specific co-morbid conditions on ET’s prevalent population.
• Identify sub-populations within ET which require treatment.
• Gain an understanding of the specific markets that have the largest number of ET patients.
• Introduction
• Cause of the Disease
• Risk Factors & Prevention
• Diagnosis of the Disease
• Variation by Geography/Ethnicity
• Disease Prognosis & Clinical Course
• Key Co-morbid Conditions/Features Associated with the Disease
• Methodology for Quantification of Patient Numbers
• Top-Line Prevalence for Essential Thrombocythemia
• Features of Essential Thrombocythemia Patients
o Type of Thrombotic Events
o Abnormal Organ Enlargement Associated with ET
o Blood Cell Associated Conditions
o Gene Mutations in ET
• Abbreviations used in the Report
• Other Black Swan Analysis Publications
• Black Swan Analysis Online Patient-Based Databases
• Patient-Based Offering
• Online Pricing Data and Platforms
• References
• Appendix
• WHO classification criteria for ET diagnosis
• Prevalence of Essential Thrombocythemia, total (000s)
• Prevalence of Essential Thrombocythemia, males (000s)
• Prevalence of Essential Thrombocythemia, females (000s)
• Type of thrombosis in Essential Thrombocythemia patients, total (000s)
• History of thrombotic event in Essential Thrombocythemia patients, total (000s)
• Site of arterial thrombosis in Essential Thrombocythemia patients, total (000s)
• Site of venous thrombosis in Essential Thrombocythemia patients, total (000s)
• Prevalence of splenomegaly in Essential Thrombocythemia, total (000s)
• Prevalence of hepatomegaly in Essential Thrombocythemia, total (000s)
• Prevalence of myelofibrosis (SMF) in Essential Thrombocythemia, total (000s)
• Prevalence of anaemia in Essential Thrombocythemia, total (000s)
• Prevalence of JAK2 mutation in Essential Thrombocythemia patients, total (000s)
• Abbreviations and Acronyms used in the report
• USA Prevalence of Essential Thrombocythemia by 5-yr age cohort, males (000s)
• USA Prevalence of Essential Thrombocythemia by 5-yr age cohort, females (000s)
• France Prevalence of Essential Thrombocythemia by 5-yr age cohort, males (000s)
• France Prevalence of Essential Thrombocythemia by 5-yr age cohort, females (000s)
• Germany Prevalence of Essential Thrombocythemia by 5-yr age cohort, males (000s)
• Germany Prevalence of Essential Thrombocythemia by 5-yr age cohort, females (000s)
• Italy Prevalence of Essential Thrombocythemia by 5-yr age cohort, males (000s)
• Italy Prevalence of Essential Thrombocythemia by 5-yr age cohort, females (000s)
• Spain Prevalence of Essential Thrombocythemia by 5-yr age cohort, males (000s)
• Spain Prevalence of Essential Thrombocythemia by 5-yr age cohort, females (000s)
• UK Prevalence of Essential Thrombocythemia by 5-yr age cohort, males (000s)
• UK Prevalence of Essential Thrombocythemia by 5-yr age cohort, females (000s)
• Brazil Prevalence of Essential Thrombocythemia by 5-yr age cohort, males (000s)
• Brazil Prevalence of Essential Thrombocythemia by 5-yr age cohort, females (000s)
• Japan Prevalence of Essential Thrombocythemia by 5-yr age cohort, males (000s)
• Japan Prevalence of Essential Thrombocythemia by 5-yr age cohort, females (000s)
• India Prevalence of Essential Thrombocythemia by 5-yr age cohort, males (000s)
• India Prevalence of Essential Thrombocythemia by 5-yr age cohort, females (000s)
+1 888 709 8757
Chat With Us